Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GCKR | Q14397 | 3/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15179487 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15168429 | 0.99 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15168048 | 0.99 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL325111 | 0.88 | CNR2 (0.49) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15168744 | 0.87 | CNR2 (0.49) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL15169087 | 0.85 | CNR2 (0.45) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10239277 | 0.84 | ALDH1A1 (0.44) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL17452474 | 0.83 | ALDH1A1 (0.47) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL16199558 | 0.82 | PRMT1 (0.45) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10239578 | 0.82 | PRMT1 (0.45) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | claimed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| EP-2590953-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | CYP1A2 654/4885CYP2C19 1661/4885ALDH1A1 2584/4885 |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | CYP1A2 654/4885CYP2C19 1661/4885ALDH1A1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.